Industry News

Cytiva Introduces New Cell Manufacturing Lines for Viral Vectors

Viral vector-based gene therapies hold immense promise for treating a multitude of diseases. However, their widespread adoption has been hindered by inefficient manufacturing methods and the absence of established standardized processes, resulting in high costs and...

Top 10 Best-Selling Cell and Gene Therapies

When it comes to cell and gene therapy revenues, it’s feast or famine. The feast side is well covered in this A-List, which ranks the top 10 therapies according to sales figures from 2023. The famine side begins almost exactly where this A-List ends. Future A-Lists...

Cytiva Introduces ELEVECTA Cell Lines

Global life sciences company, Cytiva, is creating solutions to the challenges of viral vector-based gene therapies with its new ELEVECTA cell lines. According to Emmanuel Abate, President Genomic Medicine, Cytiva: “To make gene therapy a realistic option for more...

Researchers explore new cell target for cystic fibrosis treatment

Schematic model of working hypothesis of how (A) pulmonary ionocytes and (B) club cells function in pHBE cell culture stimulated with forskolin plus IBMX. Credit: American Journal of Respiratory and Critical Care Medicine (2024). DOI: 10.1164/rccm.202309-1565OCA team...

Regeneron & Mammoth Partner on CRISPR Therapies

Regeneron Pharmaceuticals Inc. and Mammoth Biosciences Inc., have joined forces to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. Regeneron is developing adeno-associated viral vectors (AAVs) using...

Popular Services

AAV Packaging Service

AAV Analytical Service

Vector Design

Q
download_AAV-brochure